E 688
Alternative Names: B7H3 x Sialidase - Palleon Pharmaceuticals; E-688Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Palleon Pharmaceuticals
- Class Antineoplastics; Enzymes; Fab fragments; Immunoconjugates; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Neuraminidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Jan 2025 Preclinical trials in Cancer in USA (Parenteral) prior to January 2025 (Palleon Pharmaceuticals pipeline, January 2025)
- 14 Oct 2022 Palleon Pharmaceuticals has patent protection for use of antibody sialidase conjugates in USA
- 28 Jun 2022 E 688 licensed to Henlius Biopharmaceuticals in China, Hong Kong, Macau, and Taiwan